Clinical trials: Patients at Risk for Melanoma
Patients at Risk for Melanoma
Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo
This is a phase II intervention to propose a new melanoma chemoprevention agent. The investigators believe oxidative stress/damage in nevi is a probable indication for melanoma risk, and propose that reduced melanoma risk in…
- Trial name
- NCT01612221
- Testing
- N-acetylcysteine
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Utah
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.
Patients with locally advanced melanoma are at high risk for recurrence following surgical treatment. More patients with stage IV melanoma remain in complete remission following systemic therapy.
- Trial name
- DW-MRi (NCT02907827)
- Testing
- follow up DW MRI
- Where
- 2 sites in Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Patients at Risk for Melanoma
COPARIME: Pilot Study of a Target Detection of Malignant Melanoma
Melanoma is nowadays an important public health problem because its growing incidence. Mass screening for melanoma is not recommended worldwide because of its low cost-effectiveness.
- Trial name
- NCT01610531
- Testing
- SAMScore questionnaire
- Where
- France
- Volunteers
- 4,118 people
- Sponsor
- Nantes University Hospital
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
This phase II clinical trial studies how well thermal ablation and spine stereotactic radiosurgery work in treating patients with cancer that has spread to the spine (spine metastases) and is at risk for compressing the spinal…
- Conditions
- Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine
- Trial name
- NCT02713269
- Testing
- Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Precancerous Condition, Stage 0 Melanoma
Lovastatin in Treating Patients At High Risk of Melanoma
The use of lovastatin may slow disease progression in patients at high risk of melanoma. It is not yet known whether lovastatin is more effective than a placebo in treating patients at high risk of melanoma.
- Conditions
- Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
- Trial name
- NCT00462280
- Testing
- lovastatin, biopsy, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Melanoma Stage III
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for…
- Conditions
- Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin)
- Trial name
- PIVOT-12 (NCT04410445)
- Testing
- Bempegaldesleukin, Nivolumab
- Where
- 212 sites in United States, Australia and 15 more
- Volunteers
- 765 people
- Sponsor
- Nektar Therapeutics
Melanoma Stage IV, Melanoma Stage III
Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1
This is a Phase 1/2, open label, multi-centre study to assess the safety, tolerability, PD, and efficacy of adjuvant immunotherapy EVX-02 vaccine and anti-PD-1 (Nivolumab) in patients who have had a complete resection of a Stage…
- Trial name
- NCT04455503
- Testing
- EVX-02A, EVX-02B, EVX-02A OR EVX-02B
- Where
- 6 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Evaxion Biotech A/S
Lung Cancer Stage IV, Melanoma Stage IV
Screening for Brain Metastases
The survival of patients with CNS metastases often remains limited to some months. CNS metastases are also associated with neurological decline and decrease of quality of life.
- Conditions
- Lung Cancer Stage IV, Melanoma Stage IV, Breast Cancer Metastatic
- Trial name
- GAPIMET (NCT07492121)
- Testing
- gadopiclenol (contrast agent), standard contrast agent
- Where
- Switzerland
- Volunteers
- 180 people
- Sponsor
- University of Zurich
Patients at Risk for Melanoma
Optimizing Access to Care Through New Technologies: a Randomized Study Evaluating the Impact of Telephone Contact and the Sending by the General Practitioner of Suspicious Lesions Melanoma Photographs Taken With a Smartphone, on the Time Limit to the Consultation With a Dermatologist
Early detection of melanoma showed an impact on the thickness of the lesions at the time of diagnosis. One challenge is to improve the modalities.
- Trial name
- OASE Melanome (NCT03137511)
- Testing
- Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist
- Where
- France
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Melanoma
A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in participants with completely resected, cutaneous BRAF mutation-positive melanoma at high risk for…
- Trial name
- BRIM8 (NCT01667419)
- Testing
- Vemurafenib
- Where
- 207 sites in United States, Argentina and 27 more
- Volunteers
- 498 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
This study will examine the effectiveness and side effects of an experimental vaccine to prevent recurrence of melanoma. The likelihood of melanoma returning is higher in patients who have melanoma lesions deep in the skin, in…
- Trial name
- NCT00059475
- Testing
- Glycoprotein 100 (GP100): 209-217 (210M), Interleukin-2 (IL-2), Montanide ISA 51
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)